Understanding Your Treatment

With SARCLISA ESCENA™ (isatuximab-irfc) for Use With CirCLIQ™

What to expect at your appointment

Starting a new treatment often comes with questions. Here's what you can expect when receiving SARCLISA ESCENA with CirCLIQ from your healthcare provider.

SARCLISA ESCENA is administered by your healthcare provider using CirCLIQ, an on-body injector that's designed with patients like you in mind with a small, hidden, retractable needle

Before you arrive

Dress comfortably. Wear loose-fitting, comfortable clothing (other than dresses) that can be adjusted to expose your stomach, where the device will be placed.

Avoid using lotion on your stomach as it can prevent CirCLIQ from sticking properly.

Injection process

Once your healthcare provider starts the injection, the device works hands-free. You may be able to relax, read, or talk with your nurse during treatment.

When the medication has finished delivering:

- The needle retracts
- Your nurse safely removes the device and disposes of it properly

After your injection

Discuss with your healthcare provider if they will want you to remain in the clinic for monitoring.

Before you leave, make sure to schedule your next appointment.

Set aside enough time for premedication, injection, and any monitoring your doctor may require afterwards.

If you have questions at any point, your nurse and healthcare team are there to support you.

Scan the QR code

Watch a short video about receiving SARCLISA ESCENA with CirCLIQ

What is SARCLISA ESCENA?

SARCLISA ESCENA is a prescription medicine used in combination with:

- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment, and they did not work or are no longer working.
- The medicines bortezomib, lenalidomide, and dexamethasone, to treat adults with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

It is not known if SARCLISA ESCENA is safe and effective in children.

Important Safety Information

Do not receive SARCLISA ESCENA if you have a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA ESCENA (see the list of ingredients in the full Prescribing Information).

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

Important Safety Information (cont'd)

Before you receive SARCLISA ESCENA, tell your healthcare provider about all of your medical conditions, including if you:

- Have an infection.
- Have heart problems, if your healthcare provider prescribes SARCLISA ESCENA in combination with carfilzomib and dexamethasone for you.
- Have had shingles (herpes zoster).
- Are pregnant or plan to become pregnant. SARCLISA ESCENA can harm your unborn baby.

  Females who are able to become pregnant:

  – Your healthcare provider will check for pregnancy before you start treatment with SARCLISA ESCENA.

  – Use an effective birth control (contraception) during treatment and for 7 months after your last dose of SARCLISA ESCENA. Talk to your healthcare provider about birth control methods that you can use during this time.

  – Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA ESCENA.

  Females and males: Before receiving SARCLISA ESCENA in combination with either pomalidomide or lenalidomide, females and males must agree to the instructions in the pomalidomide or lenalidomide REMS programs. The pomalidomide and lenalidomide REMS programs have specific requirements about birth control, pregnancy testing, blood donation, and sperm donation that you need to know. Talk to your healthcare provider to learn more about pomalidomide or lenalidomide.
- Are breastfeeding or plan to breastfeed. It is not known if SARCLISA ESCENA passes into your breast milk. Do not breastfeed during treatment with SARCLISA ESCENA and for 7 months after your last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive SARCLISA ESCENA?

- SARCLISA ESCENA will be given to you by your healthcare provider as an injection under the skin (subcutaneous injection) in the stomach area (abdomen). Your healthcare provider will either use the CirCLIQ™ On-Body Injector or a syringe to inject SARCLISA ESCENA. Your healthcare provider will rotate the injection site for each injection, including for other medicines.
- **SARCLISA ESCENA in combination with pomalidomide and dexamethasone, or SARCLISA ESCENA in combination with carfilzomib and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
  – Cycle 1 (28-day cycle), SARCLISA ESCENA is given weekly.
  – Cycle 2 and beyond (28-day cycles), SARCLISA ESCENA is given every 2 weeks.
- **SARCLISA ESCENA in combination with bortezomib, lenalidomide, and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
  – Cycle 1 (28-day cycle), SARCLISA ESCENA is given weekly.
  – Cycles 2 to 12 (28-day cycles), SARCLISA ESCENA is given every 2 weeks.
  – Cycles 13 and beyond, SARCLISA ESCENA is given every 4 weeks.
- Your healthcare provider will decide how many treatments you will receive.
- Your healthcare provider will give you medicines before each injection of SARCLISA ESCENA, to help reduce the risk and severity of allergic reactions, for at least Cycle 1 of treatment.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the possible side effects of SARCLISA ESCENA?

SARCLISA ESCENA can cause serious side effects, including:

- **Allergic reactions.** SARCLISA ESCENA can cause severe or life-threatening allergic reactions throughout the body (systemic administration reactions). Your healthcare provider may stop your injection and not complete it or completely stop treatment with SARCLISA ESCENA if you have an allergic reaction. Tell your healthcare provider or get medical help right away if you develop any of the following signs and symptoms of an allergic reaction including:
  – shortness of breath, wheezing, or trouble breathing
  – swelling of the face, mouth, throat, or tongue
  – throat tightness
  – heart beating faster than usual
  – dizziness
  – lightheadedness or fainting
  – headache
  – cough
  – skin rash or itching
  – nausea
  – runny or stuffy nose
  – chills
- **Injection site reactions** can happen at or near the SARCLISA ESCENA injection site. Symptoms of these local skin reactions include redness, swelling, and pain. Tell your healthcare provider if you develop injection site reactions during treatment with SARCLISA ESCENA.
- **Decreased white blood cell counts.** Decreased white blood cell counts are common and can be severe during treatment with SARCLISA ESCENA. If fever occurs, this may be a sign that you have an infection. Your healthcare provider will check your blood cell counts during treatment with SARCLISA ESCENA and may prescribe medicine to help increase your white blood cell counts. **Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA ESCENA.**
- **Infections.** SARCLISA ESCENA can cause infections that are severe, life-threatening, or that can lead to death. Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with SARCLISA ESCENA. Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with SARCLISA ESCENA. **Tell your healthcare provider right away if you develop a fever or any signs or symptoms of infection during treatment with SARCLISA ESCENA.**
- **Risk of new cancers.** New cancers have happened in people during treatment with SARCLISA ESCENA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA ESCENA.
- **Change in blood tests.** SARCLISA ESCENA may affect the results of blood tests to match your blood type for at least 6 months after your last injection of SARCLISA ESCENA. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA ESCENA. **Tell all of your healthcare providers that you are being treated with SARCLISA ESCENA before receiving blood transfusions.**

The most common side effects of SARCLISA ESCENA in combination with pomalidomide and dexamethasone include:

- upper respiratory tract infection
- lung infection (pneumonia)
- tiredness
- muscle and joint pain
- diarrhea
- trouble sleeping
- COVID-19
- constipation
- swelling of the hands, legs, ankles, and feet

The most common side effects of SARCLISA ESCENA in combination with carfilzomib and dexamethasone include:

- upper respiratory tract infection
- muscle and joint pain
- lung infection (pneumonia)
- high blood pressure
- COVID-19
- trouble sleeping
- diarrhea
- fever

The most common side effects of SARCLISA ESCENA in combination with bortezomib, lenalidomide, and dexamethasone include:

- tingling or numbness of the arms or legs
- constipation
- diarrhea
- tiredness
- muscle and joint pain
- upper respiratory tract infection
- reaction at the injection site
- trouble sleeping
- nausea and vomiting
- skin rash
- skin redness
- swelling throughout the body (edema)
- COVID-19
- back pain
- low blood pressure
- lung infection (pneumonia)
- bronchitis
- muscle spasm
- weight decreased
- flu
- urinary tract infection
- fever
- abdominal pain

The most common abnormal blood test results during treatment with SARCLISA ESCENA combination therapies include:

- decreased white blood cell counts
- decreased red blood cell counts
- decreased platelet counts

Heart failure can happen during treatment with SARCLISA ESCENA in combination with carfilzomib and dexamethasone. **Tell your healthcare provider right away if you develop any of the following symptoms:**

- trouble breathing
- cough
- swelling of your ankles, feet, and legs

These are not all of the possible side effects of SARCLISA ESCENA. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

careASSIST® Sanofi Support

Everyone's treatment experience is different

That's why we offer support that's tailored to you

CareASSIST is a support program designed for people prescribed SARCLISA ESCENA, offering personalized guidance and resources.

Navigate the insurance process

Better understand your condition and treatment

Connect with resources that provide emotional, logistical, and health-related support

Pay as little as $0* out of pocket through the **CareASSIST Copay Program** pending eligibility

See if you qualify for the **CareASSIST Patient Assistance Program**, which allows you to receive your medication at no cost†

Identify other financial assistance programs that may be able to help with treatment costs

Enrolling in **CareASSIST** is easy, quick, and free.
Scan the QR code to get started

Visit **SanofiCareASSIST.com** or call one of our Case Managers at **1-833-WE+CARE** (1-833-930-2273), **Monday through Friday, 9 AM to 6 PM ET**.

***Important Notice: Subject to the program maximum per patient per calendar year.** Prescription must be for an approved indication. Not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs. Not valid where prohibited by law. This offer is nontransferable, limited to one per person, and cannot be combined with any other offer or discount. Any savings provided by the program may vary depending on patients' out-of-pocket costs. Sanofi reserves the right to modify or discontinue the program at any time without notice. All program details provided upon registration.

†Free product is provided by Sanofi Cares North America (SCNA), a charitable organization of Sanofi under Section 501(c)(3) of the IRC.

sanofi